Objectives: For over 60 years, Harborview Medical Center (HMC) 
The HMC surgeons gathered new data on plasma-based resuscitation through their personal experiences in war and in collaborations in the National Institutes of Health "Glue" Grant, the six academic trauma centers working to decode the body's cytokine response to injury, and became increasingly insistent regarding the need for speedier delivery of plasma for transfusion. 5 The UW Department of Laboratory Medicine offered to build a hospital-based transfusion service (HBTS) and, working in conjunction with the University Healthcare Consortium, identified an opportunity for substantial cost savings. Hospital leadership concluded that the necessary changes would best occur by building an HBTS. This service would allow rapid blood product delivery and actively engage in patient blood management. In January 2010, the final decision was made to build an HBTS to support the trauma program and observe the results as a guide for how to provide services to the rest of the university medical system. The new service opened April 6, 2011 .
The HMC Transfusion Service Laboratory is now 5 years old. The data demonstrate it provides blood faster, safer, and cheaper than before. It is AABB and College of American Pathologists accredited, and it has passed inspections by The Joint Commission. It has conducted developmental studies on new methods in immunohematology and supported resuscitation research by the Resuscitation Outcomes Consortium of the National Heart, Lung, and Blood Institute. This article describes the aftermath of insourcing transfusion services and the successes that have followed.
Materials and Methods
After 5 years of operation, we evaluated the effects of the HBTS by reviewing records of hospital blood use, quality system events, blood product delivery times, and costs. Furthermore, the effects of in-house expertise on laboratory medicine resident and medical laboratory scientist student training, as well as regulatory and accrediting agency concerns, were reviewed. Quantitative data allowing objective assessment were specifically sought to assess the magnitude of observed changes.
Results

Rapid Turnaround Time
The critical issue for HMC trauma surgeons was turnaround time for delivering blood components to critically hemorrhaging trauma patients. Prior to developing the HBTS, the turnaround time for plasma products was 90 minutes. Trauma surgeons waited for a specimen tube to be transported 6 city blocks for typing, type-specific plasma thawing, and thawed plasma transport back to the hospital. These times were included in the Prospective Observational Multicenter Massive Transfusion Trial and were associated with excess mortality. 6 These turnaround times would have prevented the HMC trauma center from participating in the Pragmatic Randomized Optimal Plasma and Platelets Ratio (PROPPR) trial, where turnaround time from transfusion service call to products at bedside less than 10 minutes was a required condition of study site participation. Bringing in an HBTS resulted in a mean time for thawed plasma to patient bedside of 3 minutes. Among the 12 participating North American PROPPR sites, this was second fastest while achieving the second highest enrollment. More than $2 million in research funds were brought into the institution. 7 A subsequent measure to place a blood refrigerator in the emergency department reduced wait time for plasma for trauma patients to essentially zero and, with blood on the university's patient transport helicopter system, to a negative number.
Additional factors resulted in improved turnaround time and resource management. These include maintaining a small inventory of prethawed type AB plasma while secondarily expanding this inventory with prethawed group A low-titer-B plasma and types AB and A low-titer-B liquid plasma. Liquid plasma is kept for 15 days at our institution. We also use microwaves for rapid plasma thawing, which takes approximately 5 minutes for one unit or 8 minutes for two. We use only apheresis platelets and prepooled units of cryoprecipitate to minimize unit handling in times of emergency. Finally, the transfusion service has a staff of blood runners to deliver massive transfusion packs or other requested blood component amounts in portable refrigerators to issue universal donor, type-compatible, or cross-matched blood components to critical patients in the emergency department, operating rooms, and intensive care units in massive transfusion situations.
Patient Safety
Safe blood, in the words of a World Health Organization mantra, is "the right product to the right patient in a timely manner and for the right reason." Timeliness, as noted above, has been important in saving the lives of trauma patients, but it has other benefits as well. In the prior system, in-house blood products assigned to a particular patient were cycled back to the regional center after 3 days. This created a subtle incentive © American Society for Clinical Pathology AJCP / Original article to transfuse blood while it was available. A continuously available blood supply meant transfusing "just-in-time rather than just-in-case" and has been associated with decreased blood utilization.
Making sure the right product goes to the right patient involves developing standard practices, such as requiring two independent samples for the confirmation of the ABO type. This was not required under the previous regional system but has been initiated. Education and training were further developed by the HBTS. Nurses are trained in "Blood School" taught by the nurse transfusion safety officer and medical directors. A result of these efforts is that transfusion reaction reporting has increased even though use is down because the importance of blood safety is recognized. Errors related to nurses not knowing what blood products look like or how to handle them have gone to zero. There have been no mistransfusions, no wrong-blood-in-tube events in 56,218 tubes received since the inception of the HBTS, and no serious events related to alloantibodies while 1,099 have been detected.
Patient blood management efforts focused on neurologic and orthopedic spinal surgery after a third-party external audit revealed blood utilization was above national averages in these areas. For neurosurgery, the problem was addressed with intensive physician education, including authoring a book chapter for a locally edited textbook. 8 For spinal orthopedic surgery patients, we worked with surgical staff to use blood-sparing techniques and anesthesia staff to ensure iron repletion and obtain tranexamic acid. Blood use by both services is down by more than 50% on the spine service.
At the same time, the laboratory staff has become more skilled and cohesive. Testing performed on the very first sample received on the night the laboratory opened demonstrated an alloantibody directed against k (KEL2), which was handled correctly. To improve immunohematology skills, we have taken on projects to validate commercial immunohematology analyzers, allowing comparison of results in thousands of cases of liquid, gel, and solid-phase typed or cross-matched samples. Four of our medical laboratory scientists have completed training and received the SBB certification. Technical skill is a critical but hard to measure aspect of quality and safety. [9] [10] [11] The final part of the blood safety scheme is giving blood for the right reason. As the evidence base for transfusion has increased, especially as it relates to transfusion triggers in critically ill patients, HMC's specialty, blood use has decreased markedly. This effort has been driven by the critical care physicians at HMC and supported by our transfusion medicine physicians in a growing patient blood management program with results described below.
Reduced Costs
From 2003 to 2015, the total number of blood components transfused at HMC decreased by 66% from 36,586 to 12,370 (❚Table 1❚, bottom row). The decreases in total blood components have been steady, year by year, and do not appear to have been related to the changing pattern of transfusion service support. Blood component wastage, on the other hand, has decreased from over a thousand units to less than 100 units per year and is temporally associated with the change in transfusion services.
RBC usage has decreased, with the annual totals falling from 14,560 to 7,043, a 52% overall decline in usage ( The use of cryoprecipitate decreased from approximately 3,000 units to about 300 pools/year, a 90% reduction ( Table 1 ). The change occurred almost entirely with the switch to the HBTS ❚Figure 1D❚. Much of the decrease may represent the difference between counting individual single-donor units and counting prepooled five-donor units as single transfusions. Even granting the most extreme possible numbers, total cryoprecipitate use is down by at least 50%, and the different methods of counting units of cryoprecipitate account for no more than 10% of the total reduction in blood components transfused.
As noted, all the major blood components were wasted less frequently after the opening of the HBTS. These differences were approximately 80% for RBCs, more than 90% for platelets, about 99% for plasma, and about 96% for cryoprecipitate ( Table 1) . The blood component savings come from managing small inventories well and change from 4-hour thawed time per policy of the former supplier for fresh frozen plasma to 5-day liquid storage of thawed plasma and use of 15-day liquid plasma.
Cost savings have been substantial. The new transfusion service costs about $2.5 million a year, mostly in salaries and consumables. Yearly, it saves about $2.3 million in products never purchased, $2 million in unnecessary testing and product transportation fees, and another $2 million in nursing time. Intangible benefits of not giving unnecessary blood to patients in terms of reduced hospital length of stay or morbidity are not quantified.
Shander and colleagues 12 have reported that the total cost of giving a unit of RBCs in a modern hospital was $950 in 2008 dollars. At that rate, our reduced usage translates into savings of over $7.5 million a year for RBCs and about $1.5 million a year more for platelets. Over 5 years, this amounts to over $40 million.
Discussion
The new HBTS at HMC has allowed the delivery of blood to critically hemorrhaging patients faster, safer, and cheaper. Faster service has been achieved with liquid and thawed plasma in the emergency department and transfusion service and with microwave plasma-thawing devices. Greater blood safety has been achieved with better patient identification, in-house transfusion medicine expertise, nurse education and support with a transfusion safety officer, and markedly reduced transfusion exposure. Instituting cross-match on demand-a process where type and screens are performed, and electronic cross-match is performed at issue-was key to achieving flexible inventory and reducing unnecessary testing, which enabled efficiency and cost reduction. Millions of dollars in cost savings and additional income from clinical and laboratory studies have been achieved. The new transfusion service is widely viewed as a success by hospital administration and physicians. The most recent AABB inspection found no significant deficiencies and was overseen by state and federal inspectors. The most recent American College of Surgeons CoT review of the HMC trauma program rated it the "best in the nation" and credited the blood support program as a significant part of the rating. In-hospital transfusion medicine expertise has allowed intensive training of attending and house staff physicians on blood use and safety. Providing blood quickly means that old habits of ordering blood often because it was hard to get quickly have given way to reduced transfusion because providers believe it will be available when they need it. This, coupled with academic awareness of lower transfusion triggers, appears to be the most important reason for declining usage of RBCs. 13, 14 Early hemostatic resuscitation probably accounts for most of the savings in plasma and platelets.
Lower total costs for blood have been achieved mainly through reduced blood usage. Bringing in new testing such as prenatal antibody screens and antibody titers provides additional work for nights when there is no trauma, and performing developmental testing of new solid-phase and gel automated hematology analyzers brings in funds, projects for our SBB students, and deep sophistication in immunohematology methods to reduce the need for reference testing. Some blood is also now purchased outside the local market, taking advantage of competitive pricing allowed by the stability of in-hospital inventory.
Much of the decreased blood usage is in line with national trends, but the highly academic medical staff and culture of HMC drive the very large size of the reductions described here. Safety concerns related to operating with a new staff and the lack of extensive population records of alloantibodies have not occurred because of excellent training. 15 The recognition that bringing transfusion services "in house" has made blood services faster, safer, and cheaper has not been lost on hospital administrators. Three years after opening the new HMC HBTS, the decision was made to build a similar service at the UW Medical Center. At the same time, academic advantages of the in-house expertise can be seen in the rising scores of laboratory medicine residents on their annual resident in-service exams (RISEs) and medical laboratory science students on the blood banking segments of their national licensing exams, both of which have risen by almost 100 points (a standard deviation) in the past 5 years. Part of the increase in RISE scores is likely related to a new emphasis and increased time spent on hospital-based transfusion medicine education of residents earlier in training.
Our experience shows that it is possible to build and operate a highly functional HBTS to support intense clinical and academic activity even in geographically isolated locations. It takes 1 to 2 years to build a facility and recruit and train staff to run a modern transfusion service with several years of successful operation to fully overcome historically inefficient patterns of blood use. However, with clear goals and sound methods, such a service can educate and empower academic physicians, nurses, and clinical laboratory scientists to high standards of modern hemotherapy.
